Strategies to augmentthe immuneresponse in manvia infusions of lymphokines and/or adoptive immunotherapy have extensively been performed (1, 2). The results showed that injection of lymphokine-activated killer (LAK) or tumor-infiltrating lymphocytes (TIL) resulted in tumor regression in a limited number of patients. Namely, clinically significant responses have been obtained in only 10% to 30% of the patients. One reason for limited efficacy ofLAKor TIL cells may be that only a very small number of intravenously administered LAK cells reach distant tumor sites (3). To improve the therapeutic efficacy, hepatic artery infusion of cytotoxic T lymphocytes (CTL) in patients with liver cancer was reported (4). However, among15 treated patients, 2 complete responses and 3 partial responses were only observed. These rather low response rates have raised a variety of questions about the function of the immune system in general and of T lymphocytes in particular in cancer patients. Apparent inability to develop cell-mediated antitumor immunity to the primary tumor was not due to a total lack of immuneresponse, but rather to a dynamicprocess involving the activation of suppressor T cells resulting in the inhibition of antitumor immunity in the animals (5 , 6). Hence, immunological resistance against tumor was directly dependent on the balance of the activation of CTLbearing a major role for tumor rejection and suppressor T cells capable of suppressing the activity of CTLagainst the homologous tumor (7) (8) (9) (10) . Further, Yamauchi et al. (10) reported that cytotoxic and suppressor T cells were generated under different conditions. Namely, CTL required live tumor cells for antigenic stimulation while soluble tumor antigen could activate suppressor cells. Similar findings had been reported by Taniguchi and his colleagues (1 1-13).
They described that soluble forms of tumor antigen (80Kd molecule) preferentially suppressed both induction and effector phases of antitumor CTLresponses. The concepts described in the reports are certainly based on experiments in animal systems and are not directly ready for clinical application. However, the basic observations about the suppressor-cell network in animal models have been found in humansystems (14) (15) (16) (17) (18) , and a clinically useful application of the basic observations appears inevitable.
We previously demonstrated the generation ofT-cell growth factor (TCGF)-dependent suppressor T cells from patients with systemic metastasis of gastric carcinoma (14) . The cells dominantly expressing CD8antigen were shown to inhibit the patient' s ownlymphoproliferativeresponses to alloantigen or phytohemagglutinin. Furthermore, it has been shown that TCGFactivated peripheral blood lymphocytes (PBL) from patients with advanced gastric carcinoma inhibited the effector process of tumor cell lysis by LAKcells which had been activated in vitro by rIL 2 (15, 17) . This suppression of cytotoxicity is exerted by blocking directly the activity of LAKcells. The effector cells responsible for suppression of LAKactivity showed surface phenotype of CD8+ CD1lb~in FACSsorting techniques (17) . It has also been shown that freshly obtained PBL, especially nylon-wool adherent cells from patients with advanced gastric carcinoma directly inhibit the activity of CTL and LAK cells against tumor (18) . Negative and positive selection studies by the method of immunomagnetic beads showed that CD8+T and CD8" CD1lb+ cells might be effector cells for the suppression. Possible roles of macrophageswere ruled out, since the percentages of HLA-DR+Leu M3+ cells recovered from nylon-wool adherent populations were less than 5%. These findings mean that therapeutic effect by the infusion ofCTL or LAKcells for adoptive immunotherapy will be directly inhibited by circulating CD8+ T and CD8" CD1 lb+ suppressor cells in patients with carcinoma. The generation of the suppressor cells seems to be a result of large tumor burden (14, 15, 17) . In thepresence ofsuppressorcells, immunotherapy based on the CTLor LAKcells will be ineffective; therefore, immunotherapyneeds to be conducted after such suppressor Recently, Loeffler et al. (20) reported that the decreased cytotoxic function of splenic CD8+ LAKcells generated by murine CD3and human recombinant IL 2 from late tumorbearing mice was not due to the presence of CD8+suppressor cells, but due to the impaired expression of granzyme B mRNA of the cells. Namely, they concluded that the decreased cytotoxicity of the cells was not because of cell-mediated suppression, and CD8+cells itself played a major role in the low effectiveness of adoptively transferred LAKcells from late tumor-bearing mice. However, they have not examined whether or not infusion of LAKcells with highly cytolytic activity from early tumor-bearing mice regresses the tumor mass in late tumor-bearing mice. In such situation, immunotherapeutic tumor regression would not be observed. In addition, they did not examine whether or not splenic lymphoid cells from late tumor-bearing mice directly suppressed LAKcell activity. Their experiments appear not to be proved completely for the cause of low response of adoptive immunotherapyin mice. Cohen etal. (21) reported that the expression ofHLA-DRon melanoma cells was essential for successful adoptive immunotherapy. Indeed, recent our works (22) showed that the expression of HLA-DR tended to decrease in the order of normal gastric mucosa, primary gastric carcinoma and metastatic carcinoma from malignant ascites. Thus, the low response of adoptive immunotherapy for cancer patients at the advanced stage may be partly due to the reduced expression of HLA-DR. In summary, it is reasonable to note that with the abrogation of suppressor mechanisms and the availability of large quantities of effective immune cells, clinically significant tumor burdens would be made to regress. Therefore, the realization that suppressor cells apparently develop in response to growing malignant tumorwill lead to an important newarea of research in tumor immunology.
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